Original Article

Risk of Suicidal Events in Youths Taking Atomoxetine Compared with Those on Methylphenidate; An Observational Cross-Sectional Study


Background: Stimulants such as methylphenidate and atomoxetine, a nonstimulant norepinephrine reuptake inhibitor, are approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Associations between the use of methylphenidate or atomoxetine with suicidal ideation and suicide-related behavior have been reported in the literature. The present study aimed to compare the effects of atomoxetine with that of methylphenidate on suicidal ideation and behavior in children and adolescents. Methods: Children and adolescents between 7 to 17 years of age with the diagnosis of ADHD, based on DSM-5 criteria, were included in this observational, cross sectional study. The suicidal ideation was assessed among children and adolescents who have been receiving either atomoxetine or methylphenidate for at least 12 months prior to entering the study. A Farsi version of Positive and Negative Suicide Ideation (PANSI) inventory was applied for the assessment. Differences among age groups, duration of therapy and comparison of positive and negative scores in both genders were analyzed using t-test. In addition, a one-way analysis of variance (ANOVA) was applied to examine the differences in positive and negative scores among different age groups. Moreover, chi-square and Fisher’s exact tests were performed to examine the effects of past history of drugs and other present illnesses on suicidal ideation. P-value of <0.05 was considered as significant. Results: A total of 57 students between 7 to 17 years of age were enrolled in this study. Twenty-eight patients have been taking atomoxetine at doses of 10 to 60 mg/day while 29 were on methylphenidate 7.50-55 mg/day. The mean positive and negative scores in the atomoxetine group were found to significantly differ (P=0.001) from those in the methylphenidate group. No risk of suicidal ideation was detected in the atomoxetine group, while in the methylphenidate group 15 out of 29 patients (51.7%) scored above the cutoff point. In terms of the relationship between suicidal ideation and history of other drugs prior to the current therapy and other concurrent disorders, chi-square test showed no significant difference in methylphenidate group (P=0.100 and 0.500 respectively). This analysis was not considered in atomoxetine group due to the absence of suicidal ideation. Conclusion: The authors of this study suggest that atomoxetine may be a safer choice than methylphenidate for the treatment of ADHD when suicidal ideation is a concern. In this regard, monitoring suicidal ideation and behavior along with family education should be considered in all children and adolescents suffering ADHD.

1. Rowland AS, Skipper BJ, Umbach DM, et al. The Prevalence of ADHD in a Population-Based Sample. J Atten Disord 2015;19(9):741-754.
2. Greenhill LL. Attention-deficit/hyperactivity disorder. In: Benjamin J. Sadock VAS, Pedro Ruiz, ed. Kaplan and Sadock's Comprehensive Textbook of Psychiatry Vol 2. Philadelphia: Wolters Kluwer Health; 2012.
3. Galéra C, Bouvard M, Encrenaz G, Messiah A, Fombonne E. Hyperactivity‐inattention symptoms in childhood and suicidal behaviors in adolescence: the Youth Gazel Cohort. Acta Psychiatrica Scandinavica 2008;118(6):480-489.
4. Reith DM, Edmonds L. Assessing the role of drugs in suicidal ideation and suicidality. CNS Drugs 2007;21(6):463-472.
5. Santosh PJ, Sattar S, Canagaratnam M. Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults. CNS Drugs 2011;25(9):737-763.
6. Paxton GA, Cranswick NE. Acute suicidality after commencing atomoxetine. J Paediatr Child Health 2008;44(10):596-598.
7. Wooltorton E. Suicidal ideation among children taking atomoxetine (Strattera). CMAJ 2005;173(12):1447-1447.
8. Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 2008;47(2):209-18.
9. Osman A, Barrios FX, Gutierrez PM, et al. The Positive and Negative Suicide Ideation (PANSI) Inventory: Psychometric evaluation with adolescent psychiatric inpatient samples. J Pers Assess 2002;79(3):512-30.
10. Osman A, Gutierrez PM, Kopper BA, Barrios FX, Chiros CE. The positive and negative suicide ideation inventory: Development and validation. Psychol Rep 1998;82(3):783-93.
11. Dabaghzadeh F, Ghaeli P, Khalili H, et al. Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz: a randomized clinical trial. AIDS Patient Care STDS 2013;27(3):146-54.
12. Abbasi F, Seifollahi F, Fathi Ahtiani A. validity and reliability of positive and negative suicide ideation. Annual conference in humanity research and social studies. Tehran. 2016. [originally in Persian]. https://civilica.com/doc/707825
13. McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment. Drug Saf 2009;32(11):1089-1096.
14. Linden S, Bussing R, Kubilis P, et al. Risk of suicidal events with atomoxetine compared to stimulant treatment: a cohort study. Pediatrics 2016:e20153199.
15. Chen Q, Sjölander A, Runeson B, D’Onofrio BM, Lichtenstein P, Larsson H. Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. BMJ 2014;348:g3769.
16. Bushe CJ, Savill NC. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009–2011: focus on clinical efficacy and safety. J Psychopharmacol 2014;28(3):204-211.
17. Bushe CJ, Savill NC. Suicide related events and attention deficit hyperactivity disorder treatments in children and adolescents: a meta-analysis of atomoxetine and methylphenidate comparator clinical trials. Child Adolesc Psychiatry Ment Health 2013;7(1):19.
18. Donnelly C, Bangs M, Trzepacz P, et al. Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2009;48(2):176-185.
19. Bangs ME, Wietecha LA, Wang S, Buchanan AS, Kelsey DK. Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine. J Child Adolesc Psychopharmacol 2014;24(8):426-434.
20. Capuano A, Scavone C, Rafaniello C, Arcieri R, Rossi F, Panei P. Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation. Expert Opin Drug Saf 2014;13(Suppl1):69-78.
IssueVol 9, No 4 (Autumn 2021) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/jpc.v9i4.8220
Attention Deficit Hyperactivity Disorder; Children; Methylphenidate; Atomoxetine; Suicidal Ideations Attention Deficit Hyperactivity Disorder Children Methylphenidate Atomoxetine Suicidal Ideations

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Ghaeli P, Mahmoudi-Gharaei J, Kouti L, Shakiba A, Hazara R, Alimadadi A. Risk of Suicidal Events in Youths Taking Atomoxetine Compared with Those on Methylphenidate; An Observational Cross-Sectional Study. J Pharm Care. 2021;9(4):166-170.